Applied Filters
Senate IP counsel set for Covington switch
Aaron Cooper, chief counsel for IP and antitrust law in the US Senate Judiciary Committee, is to join law firm Covington & Burling LLP.
Forest and Actavis settle over blood pressure drug
US pharmaceutical company Forest Laboratories and drug company Actavis have settled a legal dispute over a patent protecting blood pressure drug Bystoli (nebivolol).
SPC questions referred to CJEU in Actavis v Boehringer
The UK Patents Court has referred four questions to the CJEU seeking clarification on how the SPC Regulation should be interpreted in relation to drug products made of a combination of active ingredients.
Indian Patent Office rejects bid for cancer drug compulsory licence
The Indian Patent Office has rejected an application for a compulsory licence that was filed by domestic drug maker BDR Pharmaceuticals.
Arnold clears conflict of interest in SPC trial
Mr Justice Arnold has refused to recuse himself from a patent trial after he was accused of being conflicted by an expert witness.
Radcliffe leaves Mayer Brown for Charles Russell
Patent litigator Jonathan Radcliffe has left Mayer Brown to become partner at Charles Russell LLP.
Bayer takes another swipe at Nexavar compulsory licence
Bayer has appealed against the IPAB’s compulsory licence order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.
Teva wins Netherlands Copaxone case
Teva Pharmaceutical Industries has claimed victory in a patent revocation action brought by generic drug maker Mylan in the Hague over its blockbuster Copaxone drug, used in the treatment of multiple sclerosis.
FTC restricts Mylan’s acquisition of Agila amid antitrust fears
Mylan Inc will be forced to divest injectable generic drugs before it can complete a proposed $1.85 billion acquisition of Agila Specialities Global Pte Ltd and Agila Specialties Pvt Ltd after the FTC applied conditions to the deal.
India urged to improve its drugs patent policy
India’s drug patent policy has been slammed by US companies who are insisting that action be taken in order to improve trade relations.
